The promyelocytic leukemia retinoic acid receptor-a (PML-RARa) fusion gene is essential for both the initiation and perpetuation of acute promyelocytic leukemia (APL), and, consistent with its central pathogenic role, the effectiveness of all-trans retinoic acid (ATRA) and arsenic trioxide in the treatment of APL has been linked to the targeted destruction of PML-RARa. 1 Over many years, adjustments of therapy with ATRA in combination with chemotherapy for the initial treatment of APL has achieved long-term remission rates, apparent disease cure, in X85% of new APL patients. 2 In two North American phase III clinical trials employing ATRA/chemotherapy (E2491 and C9710), mutations in the ligand-binding domain (LBD) of PML-RARa were found in 30-40% of the minority of patients who relapsed (see Gallagher et al. 3 and Gallagher et al. 4 and manuscript in preparation). In four of six patients from protocol E2491 who relapsed with LBD mutations, the APL clone harboring the mutation emerged and replaced the previously predominant wild-type PML-RARa APL cell population long after the last treatment with ATRA. 3 These observations suggested that LBD mutation-harboring clones might selectively acquire ATRA-independent mechanism(s) of increased APL cell proliferation/survival competitiveness, and that this mechanism(s) might be favored in late relapse patients. In a collaborative effort to further explore this possibility, samples from previously reported late relapse patients, that is, relapse after 44 years, 5 were not available; however, eight relapse samples from patients with a relatively long interval to first relapse (median, 1015 days after treatment on French-Belgian-Swiss APL group protocol, APL2000, or off-protocol in a similar manner), 2 were available and were analyzed (Table 1) . Notably, three patients found to have LBD mutations relapsed during ATRA maintenance therapy after a median of 530 days (range, 406-557 days), whereas five patients lacking LBD mutations relapsed long after the completion of ATRA therapy after a median of 1072 days (range, 992-1249 days). The latter observation suggests that the association of late-emerging LBD mutant clones, independent of proximate ATRA selection pressure, occurs less frequently than that suggested by the previous study (current, 0/5 cases versus reported, 4/6 cases 3 ), which requires evaluation in a larger study. Further study is also required to No ATRA administered during protocol maintenance therapy.
Letters to the Editor assess whether different molecular mechanisms, and possibly different clinical consequences, are associated with LBD mutations that arise in APL clones that emerge relatively early while on ATRA therapy versus those that arise later off ATRA therapy. Unanticipated findings of this study were the uncommon characteristics of the mutations in all three patients who harbored LBD mutations at relapse and the association of these mutations with reduced response to post-relapse salvage therapy. Two of these three patients had double mutations (patients 6 and 8; Table 2 ). Recombinant cloning and DNA sequencing showed that the individual mutations were present in separate PML-RARa transcripts (shown for patient 6 in Figure 1a ). This was important to test, because in an alternative mutant fusion-gene/targeted-agent oncosystem, mutated BCR-ABL in imatinib-treated chronic myeloid leukemia, the presence of double mutations in the same BCR-ABL transcript was associated with increased drug resistance and disease progression. 6 Two of the missense mutations present in the double mutant cases, R276W and R272W (Figures 1a and c), have been redundantly reported and are associated with decreased ATRA binding, owing to disruption of the interaction of basic arginine residues with the carboxylate tail of ATRA in the RARa receptorbinding pocket by the substitution of hydrophobic tryptophan. 3, 7 Although not yet analyzed, the novel N298S mutation is also situated in the binding pocket region of the RARa receptor (Figures 1c and d) . Thus, the characteristics of these missense mutations are consistent with a role in producing ATRA resistance and having a selection effect associated with relapse while receiving ATRA maintenance therapy.
More importantly, two of the three patients had mutations that produced deletions in the LBD of PML-RARa, including double mutant patient 6. In the latter patient, the chromatographic signal for the deletion-encoding transcript was stronger than the missense-encoding transcript (R267W), indicating that the deletion-harboring APL clone predominated at disease relapse ( Figure 1a ). This mutation was produced by defective mRNA splicing at the end of RARa exon 4, resulting in the insertion of 547 nucleotides of the succeeding RARa intron 4 sequence followed by aberrant splicing in the 3 0 -terminus of RARa (deletion ¼ 630 nucleotides). The incorporated intronic sequences introduced a stop codon 19 residues downstream from the insertion site, which was only 4 amino acids beyond the end of the DNA-binding domain of RARa (Figures 1a and d) . Thus, at the transcript level, this was an insertion/truncation (ins/ trn) mutation, but at the functional protein level, it involved an extensive deletion of the entire LBD as well as the more proximal hinge region that contains the Co-R box essential for corepressor protein binding (Dhinge-LBD). 7 Unfortunately, neither relapse cells (needed to assess the effect on cell phenotype of this unprecedented mutant PML-RARa) nor genomic DNA (needed to determine the genetic basis of the mutation) was available. Of note, this patient as well as patient 8 with a double mutation had trisomy 8 before treatment (Table 1) , which has been associated with either small genomic deletion mutations or copy number neutral loss of heterozygosity in APL. 8 The other deletion mutation, D227-229 in patient 7, eliminated the codons for three amino acids with an in-frame shift to an alternative residue (DKFS/M; Figure 1b ). This mutation was present in the less frequently affected proximal region of the LBD (Figure 1d) .
All eight relapse patients in this study achieved a second clinical remission (Table 2) . In contrast to all five non-mutant cases, however, the three mutant cases relapsed for a second time, likely related to ATRA resistance imparted by the LBD mutations. After intensive therapy with arsenic trioxide and gentuzumab ozogamicin for induction, consolidation and maintenance, patient 8, who had two clones harboring different missense mutations at first relapse, entered a stable third clinical remission (Table 2 ). However, the two patients with total or focal PML-RARa LBD deletion mutations succumbed to their disease after second or third relapse, respectively (Table 2 ). In patient 6, second relapse occurred despite the use of arsenic trioxide consolidation therapy, suggesting that targeting the PML region of PML-RARa by arsenic trioxide, 1 which would include the truncation mutant clone, was insufficient to prevent disease recurrence. Similarly, all three alternatively reported APL patients who relapsed with LBD deletion mutations on protocols E2491 and C9710 succumbed to their disease during the protocol follow-up period (one on ATRA, two off ATRA; see Gallagher et al. 3 and Gallagher et al. 4 and manuscript in preparation). Together, these observations suggest that the infrequent patients who relapse with deletion or insertion/truncation mutations in PML-RARa are at increased risk of poor clinical outcome. Further studies are needed to verify this association and to determine whether the putative Letters to the Editor resistance to salvage therapy in these cases is related to inherent properties of the mutant PML-RARas or to their presence in clones with increased genetic instability that coincidently, or possibly cooperatively, give rise to alternative resistance-generating molecular aberrations. These results also suggest that testing for RARa-region mutations at first relapse after ATRA/ chemotherapy failure may be of prognostic importance in APL.
The Wilms tumor 1 (WT1) gene, located on chromosome band 11p13, encodes a transcriptional regulator involved in normal hematopoietic development. The WT1 protein contains an N-terminal domain (exons 1-6) and a C-terminal domain with 4 zinc finger motifs (exons 7-10). The role of WT1 in acute leukemia has been underscored by the finding of WT1 overexpression in most cases of acute myeloid leukemia (AML).
1 WT1 mutations have been identified in B10% of patients with AML and have been found to predict poor outcome.
2-4 WT1 mutations in T-lineage acute lymphoblastic leukemia (T-ALL) were first described more than 10 years ago by King-Underwood and Pritchard-Jones 5 in one pediatric case, but were no longer investigated until recently. Our aim was to evaluate the frequency, main associated features and prognostic significance of WT1 mutations in a cohort of children with T-cell malignancies.
A total of 157 children, aged between 7 months and 17 years, with newly diagnosed T-ALL (n ¼ 143) or T-cell lymphoblastic lymphoma (n ¼ 14), were included in this study. Patients were treated according to two consecutive clinical protocols conducted by the CLG-EORTC (Childrens Leukemia Group of the European Organisation for Research and Treatment of Cancer): studies 58881 and 58951. These protocols have been accepted by the EORTC Protocol Review Committee and by the Ethics Committee of each participating center. Informed consent was obtained from the patients or their guardians, in accordance with the declaration of Helsinki. The main characteristics of the T-ALL patients studied are described in Table 1 . T-cell lineage assessment and classification were performed according to the European Group for the Immunological Characterization of Leukemias (EGIL) recommendations. 6 Standard karyotype and screening of MLL rearrangements by fluorescent in situ hybridization analysis were performed at the time of diagnosis. The presence of an overexpression of HOX11/TLX1, HOX11L2/ TLX3 and HOXA10 genes, as well as that of SIL-TAL, CALM-AF10 and NUP214-ABL fusion transcripts was assessed by realtime quantitative reverse transcriptase-PCR as described elsewhere.
7 WT1 expression level was measured by real-time quantitative reverse transcriptase-PCR using the European Leukemia Net Standardized Assay.
1 MYB duplications were detected by gene dosage using real-time quantitative PCR. 8 Mutations of NOTCH1 exons 26, 27, 28 and 34, FBXW7 exons 9 and 10, and WT1 exon 7 and 9 were screened by direct sequencing, as described previously.
3,9,10 Statistical analysis of patient characteristics was performed using the Fisher exact test for binary variables and the Mann-Whitney test for continuous variables. Event-free survival and overall survival were
